Charles River Laboratories Inte
180.15-7.78 (-4.14%)
Oct 29, 4:00:02 PM EDT · NYSE · CRL · USD
Key Stats
Market Cap
8.87BP/E (TTM)
-Basic EPS (TTM)
-1.30Dividend Yield
0%Recent Filings
8-K
CFO transition announced
Charles River Laboratories announced on September 12, 2025, that CFO Flavia H. Pease will resign effective September 29, 2025, to pursue another opportunity, with no disagreements on company matters. Michael G. Knell, the 49-year-old Chief Accounting Officer since 2017, steps in as interim CFO until a permanent hire. The board launched a search for a successor. No disruption expected. The company reaffirms its 2025 revenue and non-GAAP EPS guidance amid a challenging demand environment.
8-K
Q2 revenue edges up, probe closed
Charles River Laboratories reported Q2 2025 revenue of $1.03 billion, up 0.6% from last year but down 0.5% organically, with DSA segment revenue falling 2.4% on lower volumes yet non-GAAP EPS climbing 11.4% to $3.12 on margin gains and restructuring savings. The company closed its U.S. DOJ probe into non-human primate shipments, easing a key overhang. Guidance now sees organic revenue down 3.0% to 1.0% for 2025, with non-GAAP EPS at $9.90–$10.30. Restructuring costs persist.
10-Q
Q2 FY2025 results
Charles River Laboratories posted Q2 revenue of $1.03B, up 0.6% y/y but flat q/q (derived), with DSA dipping 1.5% y/y from cautious biopharma spending while RMS and Manufacturing grew 3.3% and 4.4% y/y on model and microbial demand. Operating income fell to $100.1M from $151.7M y/y, pressured by $35.5M accelerated amortization on lost CDMO clients and $32.2M restructuring charges for site consolidations, yet margins held at 9.7%. Diluted EPS of $1.06 matched basic on 49.3M shares, down from $1.74 y/y with no anti-dilution flagged. Cash swelled to $182.8M, FCF hit $281.7M (derived from $376.3M operating cash minus $94.6M capex), up y/y, while debt climbed to $2.33B including $813M revolver draw. Restructuring eyes $225M annual savings. Tariffs on key suppliers like China pose supply risks.
8-K
CEO term extended; board refreshed
Charles River Laboratories extended CEO James C. Foster's employment to February 12, 2027, via an amendment approved on May 20, 2025, signaling board confidence amid leadership transitions. Shareholders elected seven directors at the annual meeting that day, appointed four new board members to fill vacancies, and approved executive pay and auditors while rejecting a PETA proposal on primate imports. Stability holds firm. The amendment leaves other terms intact.
8-K
Board refresh and strategic review
Charles River Laboratories inked a cooperation agreement with Elliott Investment Management on May 6, 2025, paving the way for four new directors—Steven Barg, Mark Enyedy, Abraham Ceesay, and Paul Graves—to join the board right after the May 20 annual meeting, while four incumbents bow out. This shake-up caps the board at 11 members and tasks the Strategic Planning and Capital Allocation Committee, now including Elliott picks, with a full business review to boost long-term shareholder value. Board refresh brings fresh expertise. Yet risks linger in executing the review.
IPO
Website
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
174.78-3.50
DHR
Danaher Corporation
214.01-2.89
ICLR
ICON plc
165.95-11.78
IDXX
IDEXX Laboratories, Inc.
627.66-6.70
IQV
IQVIA Holdings, Inc.
217.83-0.30
LH
Labcorp Holdings Inc.
248.14-11.55
NOTV
Inotiv, Inc.
1.33-0.01
RVTY
Revvity, Inc.
95.30-1.15
TMO
Thermo Fisher Scientific Inc
558.31+0.68
WAT
Waters Corporation
343.47-2.48